P/E ratio for Arrowhead Pharmaceuticals (ARWR)
P/E ratio as of March 2025 (TTM): -8.19
According to Arrowhead Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -8.19412. At the end of 2022 the company had a P/E ratio of -27.8.
P/E ratio history for Arrowhead Pharmaceuticals from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -27.8 | -26.25% |
| 2021 | -37.7 | -50.41% |
| 2020 | -76.0 | -165.87% |
| 2019 | 115 | -425% |
| 2018 | -35.5 | 362.86% |
| 2017 | -7.67 | 483.66% |
| 2016 | -1.31 | -67.75% |
| 2015 | -4.07 | -23.84% |
| 2014 | -5.35 | -33.88% |
| 2013 | -8.09 | 640.8% |
| 2012 | -1.09 | -87.23% |
| 2011 | -8.55 | -14.01% |
| 2010 | -9.94 | 406.6% |
| 2009 | -1.96 | 57.89% |
| 2008 | -1.24 | -72.04% |
| 2007 | -4.45 | -40.1% |
| 2006 | -7.42 | -41.89% |
| 2005 | -12.8 | -11.1% |
| 2004 | -14.4 | 626.42% |
| 2003 | -1.98 | 1610.19% |
| 2002 | -0.1157 | -61.49% |
| 2001 | -0.3004 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 | -65.5 | 699.37% | 🇺🇸 USA |
 | N/A | N/A | 🇺🇸 USA |
 | 68.8 | -940.20% | 🇺🇸 USA |
 | -2.69 | -67.14% | 🇺🇸 USA |
 | 11.5 | -240.12% | 🇺🇸 USA |
 | -3.44 | -57.97% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.